Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance
暂无分享,去创建一个
W. Foulkes | C. Hawkins | G. Nicholas | D. Stearns | M. Link | D. Malkin | K. Nichols | M. Blundell | M. Yalon | S. Constantini | Bailey Gallinger | H. Baris | M. Remke | H. Toledano | Y. Goldberg | Donald G Basel | S. Ben-Shachar | S. Zimmermann | E. Atenafu | M. Massimino | D. Gass | C. Kratz | Zehavit Frenkel | A. Bendel | U. Tabori | E. Bouffet | R. Dvir | M. Rashid | H. Hampel | L. Reichman | Catherine Goudie | Musa Alharbi | J. Hansford | D. Sumerauer | D. Ziegler | V. Larouche | E. Opocher | M. Aronson | G. Mason | D. Blumenthal | R. Kebudi | M. Sabel | Á. Lassaletta | N. Hijiya | S. Zelcer | Rebecca C. Luiten | C. Durno | R. Pearlman | S. Gardner | N. Mushtaq | Abeer Al-Battashi | T. Nicolaides | C. Koschmann | C. Swallow | A. Reddy | L. Taylor | A. Bronsema | J. Maciaszek | M. Ghalibafian | I. Scheers | B. Oshrine | Anirban Das | J. Kamihara | S. Chiaravalli | David Samuel | O. Maher | A. Ercan | A. Van Damme | R. McGee | B. Crooks | S. Sen | A. Villani | M. Osborn | S. Lindhorst | R. Bedgood | I. Winer | A. Chamdin | K. Schneider | R. Farah | J. Knipstein | C. Harlos | Sumita Roy | M. Edwards | M. Bornhorst | Gadi Abebe-Campino | C. Gilpin | S. A. Hamid | S. Caspi | V. Bianchi | Patrick Tomboc | L. Yen | Gabriel Robbins | Sarah L. Rhode | V. F. Azad | S. Ling | M. Lurye | Melissa A. Galati | S. Hsu | M. Zápotocký | Daniel Pettee | Gregory A. Thomas | R. Loret de Mola | Elizabeth Cairney | Vanan MagimairajanIssai | M. Newmark | J. Rapp | Valérie Larouche | R. Loret De Mola | Monica Newmark
[1] S. Kirmani,et al. Position paper: Challenges and specific strategies for constitutional mismatch repair deficiency syndrome in low‐resource settings , 2020, Pediatric blood & cancer.
[2] Raymond Y Huang,et al. Mechanisms and therapeutic implications of hypermutation in gliomas , 2020, Nature.
[3] Victoria Hagens,et al. Consolidated principles for screening based on a systematic review and consensus process , 2018, Canadian Medical Association Journal.
[4] J. Sterne,et al. Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial , 2018, JAMA.
[5] K. Cole,et al. Comprehensive Analysis of Hypermutation in Human Cancer , 2017, Cell.
[6] D. Evans,et al. Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 1 , 2017, Clinical Cancer Research.
[7] D. Evans,et al. Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 2 and Related Disorders , 2017, Clinical Cancer Research.
[8] T. Druley,et al. Recommendations for Surveillance for Children with Leukemia-Predisposing Conditions , 2017, Clinical Cancer Research.
[9] S. Plon,et al. Clinical Management and Tumor Surveillance Recommendations of Inherited Mismatch Repair Deficiency in Childhood , 2017, Clinical Cancer Research.
[10] D. Lieberman,et al. Recommendations on Surveillance and Management of Biallelic Mismatch Repair Deficiency (BMMRD) Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. , 2017, Gastroenterology.
[11] B. Burkhardt,et al. Non-Hodgkin lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescents , 2016, Haematologica.
[12] D. Merico,et al. Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Schiffman,et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. , 2016, The Lancet. Oncology.
[14] Z. Cohen,et al. Gastrointestinal Findings in the Largest Series of Patients With Hereditary Biallelic Mismatch Repair Deficiency Syndrome: Report from the International Consortium , 2016, The American Journal of Gastroenterology.
[15] G. Leverger,et al. Constitutional mismatch repair deficiency syndrome: clinical description in a French cohort , 2015, Journal of Medical Genetics.
[16] Monica Stanciu,et al. Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide. , 2015, Cancer research.
[17] K. Nichols,et al. Diagnostic Performance of Whole-Body MRI as a Tool for Cancer Screening in Children With Genetic Cancer-Predisposing Conditions. , 2015, AJR. American journal of roentgenology.
[18] C. Hawkins,et al. Phenotypic and genotypic characterisation of biallelic mismatch repair deficiency (BMMR-D) syndrome. , 2015, European journal of cancer.
[19] Roland Arnold,et al. Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers , 2015, Nature Genetics.
[20] A. Shaaban,et al. Role of rapid sequence whole-body MRI screening in SDH-associated hereditary paraganglioma families , 2014, Familial Cancer.
[21] A. Duval,et al. Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium ‘Care for CMMRD’ (C4CMMRD) , 2014, Journal of Medical Genetics.
[22] C. Hawkins,et al. Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium. , 2014, European journal of cancer.
[23] A. Duval,et al. Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium “Care for CMMR-D” (C4CMMR-D) , 2014, Journal of Medical Genetics.
[24] S. Gallinger,et al. Oncologic surveillance for subjects with biallelic mismatch repair gene mutations: 10 year follow‐up of a kindred , 2012, Pediatric blood & cancer.
[25] L. Loeb,et al. Human cancers express mutator phenotypes: origin, consequences and targeting , 2011, Nature Reviews Cancer.
[26] J. Beyene,et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. , 2011, The Lancet. Oncology.
[27] B. Preston,et al. DNA replication fidelity and cancer. , 2010, Seminars in cancer biology.
[28] K. Wimmer,et al. Constitutional mismatch repair-deficiency syndrome , 2010, Haematologica.
[29] Rebecca A Betensky,et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. , 2007, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] M. Yaffe,et al. American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography , 2007, CA: a cancer journal for clinicians.
[31] J. Jiricny. The multifaceted mismatch-repair system , 2006, Nature Reviews Molecular Cell Biology.
[32] Tracy T Batchelor,et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. , 2006, Cancer research.
[33] J. Kleibeuker,et al. Decrease in mortality in Lynch syndrome families because of surveillance. , 2006, Gastroenterology.
[34] A. Fedier,et al. Mutations in DNA mismatch repair genes: implications for DNA damage signaling and drug sensitivity (review). , 2004, International journal of oncology.
[35] F. Berthold,et al. Neuroblastoma screening at one year of age. , 2002, The New England journal of medicine.
[36] L. F. Engebretsen,et al. A homozygote splice site PMS2 mutation as cause of Turcot syndrome gives rise to two different abnormal transcripts , 2008, Familial Cancer.
[37] P. Karran,et al. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer , 2008, Nature Reviews Cancer.